134 related articles for article (PubMed ID: 12970151)
1. Complete regression of advanced HCC with long acting octreotide.
Siveke JT; Herberhold C; Folwaczny C
Gut; 2003 Oct; 52(10):1531. PubMed ID: 12970151
[No Abstract] [Full Text] [Related]
2. Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.
Cebon J; Findlay M; Hargreaves C; Stockler M; Thompson P; Boyer M; Roberts S; Poon A; Scott AM; Kalff V; Garas G; Dowling A; Crawford D; Ring J; Basser R; Strickland A; Macdonald G; Green M; Nowak A; Dickman B; Dhillon H; Gebski V;
Br J Cancer; 2006 Oct; 95(7):853-61. PubMed ID: 16953241
[TBL] [Abstract][Full Text] [Related]
3. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study.
Becker G; Allgaier HP; Olschewski M; Zähringer A; Blum HE;
Hepatology; 2007 Jan; 45(1):9-15. PubMed ID: 17187405
[TBL] [Abstract][Full Text] [Related]
4. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide].
Allgaier HP; Becker G; Blum HE
Dtsch Med Wochenschr; 2000 Mar; 125(11):320. PubMed ID: 10761474
[No Abstract] [Full Text] [Related]
5. Octreotide treatment of hepatocellular carcinoma.
Kouroumalis E; Samonakis D; Skordilis P
Hepatology; 2003 Feb; 37(2):477. PubMed ID: 12540801
[No Abstract] [Full Text] [Related]
6. Octreotide in hepatocellular carcinoma.
Shouval D
Gut; 1998 Mar; 42(3):316-7. PubMed ID: 9577332
[No Abstract] [Full Text] [Related]
7. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
[TBL] [Abstract][Full Text] [Related]
8. Complete, long-standing regression of hepatocellular carcinoma after somatostatin analogue treatment.
Rahmi G; Malka D; Tomasic G; Dromain C; Ducreux M; Boige V
J Clin Oncol; 2007 Jun; 25(16):e15-6. PubMed ID: 17538153
[No Abstract] [Full Text] [Related]
9. The results of a randomized study on the use of long-acting octreotide in hepatocellular carcinoma.
Borbath I; Horsmans Y
Hepatology; 2003 Feb; 37(2):477-8; author reply 478. PubMed ID: 12575712
[No Abstract] [Full Text] [Related]
10. [Somatostatin analogue (octreotide)].
Sano K; Makuuchi M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():674-7. PubMed ID: 11762035
[No Abstract] [Full Text] [Related]
11. Octreotide and hepatocellular carcinoma.
Farinati F; Sergio A; Baldan A; Zucchetta P; Corleto VD
Br J Cancer; 2007 Jun; 96(11):1778-9. PubMed ID: 17505506
[No Abstract] [Full Text] [Related]
12. Octreotide for unresectable hepatocellular carcinoma: beyond the first sight.
Samonakis DN; Christodoulakis N; Kouroumalis EA
J Clin Gastroenterol; 2006 Jan; 40(1):86-7. PubMed ID: 16340641
[No Abstract] [Full Text] [Related]
13. Octreotide inhibits the growth and development of three types of experimental liver metastasis.
Frizelle FA
Br J Surg; 1995 Nov; 82(11):1577. PubMed ID: 8535822
[No Abstract] [Full Text] [Related]
14. Somatostatin and hepatocellular carcinoma.
Kapadia CR
Gastroenterology; 1998 Nov; 115(5):1298-9. PubMed ID: 9797392
[No Abstract] [Full Text] [Related]
15. Octreotide therapy for advanced hepatocellular carcinoma.
Slijkhuis WA; Stadheim L; Hassoun ZM; Nzeako UC; Kremers WK; Talwalkar JA; Gores GJ
J Clin Gastroenterol; 2005 Apr; 39(4):333-8. PubMed ID: 15758629
[TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
18. Octreotide therapy for hepatocellular carcinoma: a systematic review of the evidence from randomized controlled trials.
Jia WD; Zhang CH; Xu GL; Ge YS; Wang W
Hepatogastroenterology; 2010; 57(98):292-9. PubMed ID: 20583430
[TBL] [Abstract][Full Text] [Related]
19. Regression of a hepatocellular carcinoma following treatment with octreotide and tamoxifen in a patient with advanced alcoholic cirrhosis.
Senturk H; Canbakan B; Cumali R
J Gastroenterol Hepatol; 2004 Jun; 19(6):719-20. PubMed ID: 15151636
[No Abstract] [Full Text] [Related]
20. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
